Skip to main content
. 2016 Dec 29;107(12):1843–1850. doi: 10.1111/cas.13098

Figure 2.

Figure 2

Kaplan–Meier plots of overall survival according to RAS and BRAF mutation status (a) and according to serum VEGF‐A level (b). Bmab, bevacizumab; CI, confidence interval; HR, hazard ratio; Pmab, panitumumab. WT,RAS or BRAF wild type; MT,RAS or BRAF mutant. sVEGF‐A, serum vascular endothelial growth factor‐A.